New imaging method could improve heart surgery outcomes for aortic stenosis patients

NCT ID NCT07469371

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special heart scan called CT-FFR can help doctors make better decisions about treating blocked arteries before valve replacement surgery. 300 patients with severe aortic stenosis will be randomly assigned to have their treatment guided by either standard scans or CT-FFR. The goal is to see if CT-FFR reduces major heart problems like heart attacks or death within one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CT-derived fractional flow reserve (CT-FFR) imaging test
What this could lead to
If successful, this could show that using CT-FFR to guide treatment decisions before valve replacement reduces the risk of heart attacks, heart failure, or death in patients with severe aortic stenosis.
What could go wrong
This is a single-center trial with 300 participants, so results may not apply to all patients. The benefit of CT-FFR over standard imaging is unproven, and the follow-up is only one year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yan'an Hospital Affiliated to Kunming Medical University

    RECRUITING

    Kunming, Yunnan, 650050, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.